1. Home
  2. ULY vs DRMA Comparison

ULY vs DRMA Comparison

Compare ULY & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urgent.ly Inc.

ULY

Urgent.ly Inc.

N/A

Current Price

$2.05

Market Cap

4.8M

Sector

N/A

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

N/A

Current Price

$1.31

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ULY
DRMA
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
4.2M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
ULY
DRMA
Price
$2.05
$1.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.50
$10.00
AVG Volume (30 Days)
25.6K
2.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$142,905,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.59
52 Week High
$17.99
$7.33

Technical Indicators

Market Signals
Indicator
ULY
DRMA
Relative Strength Index (RSI) 47.43 44.44
Support Level $1.81 $0.63
Resistance Level $2.74 $2.29
Average True Range (ATR) 0.13 0.16
MACD 0.02 0.03
Stochastic Oscillator 62.53 18.60

Price Performance

Historical Comparison
ULY
DRMA

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.

Share on Social Networks: